Method of predicting the response to treatment with IL-31 antagonists in patients suffering from diseases accompanied by pruritus

摘要

Provided is a novel therapeutic agent for a disease associated with pruritus for a patient who is determined to be a responder to treatment with an IL-31 antagonist. [MEANS FOR SOLVING PROBLEMS] (1) SERPINB3 and / or SERPINB4 in a sample obtained from a patient suffering from pruritus, which is a therapeutic agent for pruritus, comprising an IL-31 antagonist as an active ingredient , (2) S100A9, (3) CXCL1, (4) SFTPD, (5) TCHH, and (6) high expression level of at least one marker selected from the group consisting of CXCL6. A therapeutic agent for administration only to patients who are determined to be responders to treatment. The IL-31 antagonist is preferably an antibody that inhibits an IL-31 signal, such as an anti-IL-31 neutralizing antibody or an anti-IL-31RA neutralizing antibody. [Selection figure] None